natgillin/translations-raw huggingface dataset:
Any long-term inflammation, lumps (nodules) or inflammation that occur at the infusion site and last more than a few days should be reported to your physician.
O vseh primerih dolgotrajnega vnetja, vozličev ali vnetja, ki se pojavi na mestu infundiranja in traja dlje kot nekaj dni, morate obvestiti zdravnika.
The suggested site(s) for the infusion of the medicinal product are the middle to upper abdomen and thighs.
Priporočena mesta infundiranje zdravila so srednji do zgornji del trebuha in stegna.
Patients must be closely monitored throughout the infusion period, particularly patients starting with therapy.
Bolnike, zlasti tiste, ki začenjajo zdravljenje, je treba natančno spremljati skozi ves čas trajanja infuzije.
Marketing Authorisation Holder and Manufacturer
Imetnik dovoljenja za promet z zdravilom in izdelovalci
The recombinant human hyaluronidase is a protein that makes it easier for the immunoglobulins to be infused (dripped) under the skin and to reach your blood system.
Rekombinantna humana hialuronidaza je beljakovina, ki imunoglobulinom, ki se infundirajo (s kapanjem) pod kožo, olajša prehod v krvni obtok.
Infuse the full dose per site of IG 10% through the same subcutaneous needle set within 10 minutes of the recombinant human hyaluronidase.
Celoten odmerek IG 10 % na mesto infundirajte skozi isti komplet igel v 10 minutah po opravljenem infundiranju rekombinantne humane hialuronidaze.
- if you are allergic to immunoglobulins, hyaluronidase, recombinant hyaluronidase or any of the other ingredients of this medicine (listed in section 6, “Contents of the pack and other information”).
- če ste alergični na imunoglobuline, hialuronidazo, rekombinantno hialuronidazo ali katero koli sestavino tega zdravila (navedeno v poglavju 6, ”Vsebina pakiranja in dodatne informacije”), - če imate v krvi protitelesa proti imunoglobulinu A (IgA), ki so lahko posledica pomanjkljivosti
What HyQvia looks like and contents of the pack
Izgled zdravila HyQvia in vsebina pakiranja
IG 10% is a clear or slightly opalescent and colourless or pale yellow solution.
IG 10 % je bistra ali rahlo opalescentna in brezbarvna ali bledo rumena raztopina.
• Do not shake.
• Ne stresajte.
In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
V primeru neželenega učinka je treba zmanjšati hitrost dajanja ali prekiniti infundiranje.
Patients previously treated with immunoglobulin administered intravenously For patients switching directly from intravenous administration of immunoglobulin, or who have a previous intravenous dose of immunoglobulin that can be referenced, the medicinal product should be administered at the same dose and at the same frequency as their previous intravenous immunoglobulin treatment.
Bolniki, ki so bili predhodno zdravljeni z imunoglobulini, uporabljenimi intravensko Pri bolnikih, ki prehajajo neposredno z intravenske uporabe imunoglobulina ali so predhodno prejeli znan intravenski odmerek imunoglobulina, je treba zdravilo uporabiti v enakem odmerku in z enako pogostnostjo kakor prejšnje intravensko imunoglobulinsko zdravljenje.
No long-term (chronic) changes in the skin were observed in the clinical studies.
V kliničnih študijah niso opazili dolgotrajnih (kroničnih) sprememb kože.
HyQvia has to be infused under the skin (subcutaneous or SC administration).
Zdravilo HyQvia se infundira pod kožo (subkutano ali s.c. dajanje).
► In such cases, you will be closely monitored during your first infusion and for the first hour after your infusion has stopped.
► V takšnih primerih vas bodo med prvo infuzijo in v uri po končani infuziji natančno spremljali.
VIAL LABEL HUMAN NORMAL IMMUNOGLOBULIN (5 G, 10 G, 20 G AND 30 G)
NALEPKA NA VIALI HUMANEGA POLISPECIFIČNEGA IMUNOGLOBULINA (5 G, 10 G, 20 G IN 30 G)
Information on the source material of HyQvia
Informacije o izvornem materialu zdravila HyQvia
Prepare the infusion site:
Pripravite mesto infundiranja:
In these studies, maternal antibodies to recombinant human hyaluronidase were transferred to offspring in utero.
V teh študijah so se maternalna protitelesa proti rekombinantni humani hialuronidazi v maternici prenašala na potomce.
The recombinant human hyaluronidase of HyQvia contains small amounts (4.03 mg per ml) of sodium.
Rekombinantna humana hialuronidaza zdravila HyQvia vsebuje majhno količino natrija (4,03 mg na ml).
Passive transmission of antibodies to erythrocyte´s surface antigens, (e.g., A, B, D) may interfere with some serological tests for red cell antibodies for example the direct antiglobulin test (DAT, direct Coombs' test).
A, B in D) lahko moti nekatere serološke preiskave za protitelesa proti eritrocitom, npr. direktni antiglobulinski test (DAT, direktni Coombsov test).
Do not mix the components of HyQvia prior to administration.
Komponent zdravila HyQvia pred uporabo ne zmešajte.
You and your doctor will decide if you can use HyQvia at home. Do not begin treatment with HyQvia at home until you have received complete instructions.
Z zdravilom HyQvia se ne začnite zdraviti doma, dokler ne prejmete vseh navodil.
• Pull back on the plunger, fill the smaller syringe with air equal to the amount of recombinant human hyaluronidase in the HY vial(s).
• Povlecite bat in manjšo brizgo napolnite z zrakom do količine, ki je enaka količini rekombinantne humane hialuronidaze v viali (vialah) HY.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
• Insert the tip of the needle/non-vented transfer device into the center of the vial stopper and push straight downward.
• Uvedite konico igle/neprezračevanega pripomočka za prenos v sredino zamaška viale ter enakomerno potisnite.
• patients with a certain kind of blood cancer (chronic lymphocytic leukaemia) which leads to a lack of antibody production and recurrent infections when preventative antibiotics have failed.
• bolniki z določeno vrsto krvnega raka (kronično limfocitno levkemijo), ki povzroči pomanjkanje tvorbe protiteles in ponavljajoče se okužbe, ko je bilo preventivno antibiotično zdravljenje neuspešno,
How to use HyQvia
Kako uporabljati zdravilo HyQvia
You will be watched carefully throughout the infusion and for at least 1 hour after stopping the infusion to see how well you tolerate the medicine.
Med infundiranjem in še najmanj 1 uro po njem vas bodo natančno opazovali, da vidijo, kako prenašate zdravilo.
The other ingredients are sodium chloride, sodium phosphate, human albumin, ethylenediaminetetraacetic acid (EDTA) disodium, calcium chloride and water for injections (see also section 2, “HyQvia contains sodium”).
Druge sestavine so natrijev klorid, natrijev fosfat, humani albumin, dinatrijev edetat, kalcijev klorid in voda za injekcije (glejte tudi poglavje 2, ”Zdravilo HyQvia vsebuje natrij”).
• patients with a specific cancer of the bone marrow (multiple myeloma) and lack of antibody production with recurrent infections who have failed to respond to a vaccine against certain bacteria (pneumococci).
• bolniki s posebnim rakom kostnega mozga (multiplim mielomom) in pomanjkanjem tvorbe protiteles s ponavljajočimi se okužbami, ki se niso odzvali na cepivo proti določenim bakterijam (pnevmokokom),
Keep the vials in the outer carton in order to protect from light.
Viali shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
• Prepare to transfer the recombinant human hyaluronidase component of HyQvia by wiping each vial stopper with an alcohol swab, if directed and allow to air dry (at least 30 seconds).
• Komponento z rekombinantno humano hialuronidazo zdravila HyQvia na prenos pripravite tako, tako da obrišete zamašek vsake viale z alkoholnim tamponom, če je tako določeno, in pustite, da se posuši na zraku (vsaj 30 sekund).
Infusion for subcutaneous use.
Infuzija za subkutano uporabo.
• Slowly push the plunger of the smaller syringe with the recombinant human hyaluronidase at an initial rate per infusion site to approximately 1 to 2 ml per minute and increase as tolerated.
• Počasi potisnite bat manjše injekcijske brizge z rekombinantno humano hialuronidazo z začetno hitrostjo na mesto infundiranja približno 1 do 2 ml na minuto, ki jo povečujte, kolikor jo lahko prenašate.
Administer the human normal immunoglobulin 10% with a pump at the rates prescribed by your healthcare professional and start the infusion.
Humani polispecifični imunoglobulin 10 % infundirajte s črpalko s hitrostjo, ki jo je določil zdravstveni delavec, in začnite infundiranje.
Check for proper needle placement before starting the infusion if instructed by your healthcare professional.
Pred začetkom infundiranja preverite ustreznost namestitve igle, če vam je tako naročil zdravstveni delavec.
Human normal immunoglobulin vial: Glycine, water for injections.
Viala humanega polispecifičnega imunoglobulina: glicin, voda za injekcije.
• Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.
• hipogamaglobulinemiji in ponavljajočih se bakterijskih okužbah pri bolnikih z multiplim mielmom (MM),
Do not use the product if it does not have the cap.
Zdravila ne uporabite, če nima zaporke.
The same indications, dose and frequency of infusion as for adults apply for children and adolescents (0-18 years).
Za otroke in mladostnike (0-18 let) veljajo enake indikacije, odmerek in pogostnost infundiranja kot za odrasle.
VIAL LABEL RECOMBINANT HUMAN HYALURONIDASE (2.5 ML, 5 ML, 10 ML, 15 ML)
NALEPKA NA VIALI REKOMBINANTNE HUMANE HIALURONIDAZE (2,5 ML/5 ML/10 ML/15 ML)
• Prepare to transfer the immunoglobulin 10% component of HyQvia by wiping each vial stopper with an alcohol swab, if directed and allow to air dry (at least 30 seconds).
• Komponento z imunoglobulinom 10 % zdravila HyQvia na prenos pripravite tako, tako da obrišete zamašek vsake viale z alkoholnim tamponom, če je tako določeno, in pustite, da se posuši na zraku (vsaj 30 sekund).
• Allow refrigerated product to come to room temperature before use.
• Ohlajeno zdravilo pred uporabo segrejte na sobno temperaturo.
Recombinant human hyaluronidase vial: human hyaluronidase.
Viala rekombinantne humane hialuronidaze: humana hialuronidaza.
Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.
V redkih primerih lahko humani polispecifični imunoglobulin povzroči zmanjšanje krvnega tlaka z anafilaktično reakcijo, celo pri bolnikih, ki so dobro prenašali predhodno zdravljenje s humanim polispecifičnim imunoglobulinom.
No chronic changes in the skin were observed in the clinical studies.
V kliničnih študijah niso opazili kroničnih sprememb kože.
Certain adverse reactions may occur more frequently in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion.
Določeni neželeni učinki so lahko pogostejši pri bolnikih, ki prvič prejemajo humani polispecifični imunoglobulin, v redkih primerih, ko bolnik preide z drugega zdravila s humanim polispecifičnim imunoglobulinom in če je od zadnje infuzije minilo dolgo časa.
Hypersensitivity, influenza-like illness, and infusion site leakage, inflammation of the layers lining the brain (aseptic meningitis).
Preobčutljivost, bolezen, podobna gripi, in iztekanje na mestu infundiranja, vnetje možganskih ovojnic (aseptični meningitis).
Following subcutaneous administration of HyQvia, peak serum IgG levels are achieved in the recipient's circulation after approximately 3 to 5 days.
Po subkutanem dajanju zdravila HyQvia se najvišje serumske koncentracije IgG v krvnem obtoku pojavijo po približno 3 do 5 dneh.
Human normal immunoglobulin 10%
Humani polispecifični imunoglobulin 10 %
Non-clinical data reveal no special risk for humans based on conventional studies of safety pharmacology and toxicity.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti in toksičnosti ne kažejo posebnega tveganja za človeka.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped hepatitis A (HAV) and parvovirus B19 viruses.
Opravljeni postopki štejejo za učinkovite proti virusom z ovojnico, kot so virus imunske pomanjkljivosti pri človeku (HIV) in virusa hepatitisa B (HBV) in C (HCV), in proti virusoma brez ovojnice, virusu hepatitisa A (HAV) in parvovirusu B19.
HyQvia should only be used by pregnant and breast-feeding women after discussion with your physician.
Zdravilo HyQvia se sme uporabljati pri nosečnicah in doječih materah samo po posvetu z zdravnikom.
Detailed Instructions for Use are provided in the section below.
Sledi podrobno navodilo za uporabo.
The measures taken for the manufacture of HyQvia are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus and for the non-enveloped hepatitis A virus and parvovirus B19.
Postopki, uporabljeni pri izdelavi zdravila HyQvia, štejejo za učinkovite proti virusom z ovojnico, kot so virus imunske pomanjkljivosti pri človeku (HIV) in virusa hepatitisa B in C, in proti virusoma brez ovojnice, virusu hepatitisa A in parvovirusu B19.
Name and address of the manufacturers responsible for batch release
Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serij
This medicine contains trace amounts of immunoglobulin A (IgA) (not more than 140 micrograms/ml, 37 micrograms on average).
Zdravilo vsebuje imunoglobulin A (IgA) v sledovih (največ 140 mikrogramov/ml, v povprečju 37 mikrogramov).
The human normal immunoglobulin 10% of HyQvia and human serum albumin (an ingredient of the recombinant human hyaluronidase) are made from human plasma (the liquid part of blood).
Humani polispecifični imunoglobulin 10 % zdravila HyQvia in humani serumski albumin (sestavina rekombinantne humane hialuronidaze) sta pripravljena iz človeške plazme (tekočega dela krvi).
• Point the syringe tip up and remove any air bubbles by pointing the syringe tip up and gently tapping the syringe with your finger.
• Konico brizge usmerite navzgor in odstranite morebitne zračne mehurčke tako, da konico brizge usmerite navzgor in s prsti narahlo potrkate po brizgi.
Since HyQvia contains trace amounts of IgA, you might have an allergic reaction.
Ker zdravilo HyQvia vsebuje IgA v sledovih, se lahko pri vas pojavi alergijska reakcija, - v žilo (intravensko).
• Withdraw the full contents of the recombinant human hyaluronidase into the syringe.
• Vso vsebino rekombinantne humane hialuronidaze povlecite v brizgo.
Patients should be informed about first symptoms which encompass severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting.
Bolnike je treba poučiti o prvih simptomih, ki vključujejo hud glavobol, tog vrat, zaspanost, povišano telesno temperaturo, fotofobijo, slabost in bruhanje.
• Depending on the severity of associated reaction, and medical practice, pre-medication may prevent this type of reaction.
• Tovrstno reakcijo lahko prepreči premedikacija, kar je odvisno od resnosti povezane reakcije in zdravstvene prakse.
One ml of the solution in this vial contains 100 mg of human normal immunoglobulin, of which at least 98% is immunoglobulin G (IgG).
En ml raztopine v tej viali vsebuje 100 mg humanega polispecifičnega imunoglobulina, od tega je najmanj 98 % imunoglobulina G (IgG).
1 vial recombinant human hyaluronidase 1.25 ml
1 viala rekombinantne humane hialuronidaze 1,25 ml
Place all gathered supplies and open them as directed by your healthcare professional.
Na površino položite zbrane pripomočke in jih odprite po navodilu zdravstvenega delavca.
Recombinant human hyaluronidase (rHuPH20) vial 1.25, 2.5, 5, 10 or 15 ml of solution in a vial (Type I glass) with a stopper (chlorobutyl rubber).
Viala rekombinantne humane hialuronidaze (rHuPH20) 1,25; 2,5; 5; 10 ali 15 ml raztopine v viali (iz stekla vrste I) z zamaškom (iz klorobutilne gume).
Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in HyQvia, are protective.
Imunoglobulini verjetno niso bili povezani z okužbami z virusom hepatitisa A in parvovirusom B19 zaradi zaščitne vloge protiteles proti tema povzročiteljema, ki so v zdravilu HyQvia.
Uncommon (≥1/1,000 to <1/100)
Občasni (≥1/1.000 do <1/100)
This will be increased step-wise to larger doses at 3- to 4-week intervals with the next infusions.
Odmerek se bo pri naslednjih infuzijah postopno povečeval do velikih odmerkov v tri-do štiritedenskih presledkih.
The effects of antibodies that bind to recombinant human hyaluronidase on human fertility are unknown.
Učinki protiteles, ki se vežejo na rekombinantno humano hialuronidazo, na plodnost pri ljudeh niso znani.
This should be taken into consideration in patients on a controlled sodium diet.
To morajo upoštevati bolniki z nadzorovanim vnosom natrija.
The following infusion rates of the IG 10% are recommended per infusion site:
Priporočene hitrosti infundiranja IG 10 % na mesto infundiranja so naslednje:
The product should be brought to room temperature before use.
Pred uporabo morate zdravilo segreti na sobno temperaturo.
• Gently press a small piece of gauze over the needle site and cover with a protective dressing.
• Na mesto vboda previdno položite majhen košček gaze, ki ga prekrijte z zaščitno oblogo.
He or she will decide whether to slow down the infusion rate or stop the infusion completely.
Presodila bosta, ali je potrebno zmanjšati hitrost infundiranja ali infundiranje prekiniti.
Vaccinations
Cepljenje
Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.
V redkih primerih lahko humani polispecifični imunoglobulin povzroči nenadno zmanjšanje krvnega tlaka in v posameznih primerih tudi anafilaktični šok, celo pri bolnikih, ki pri predhodnem zdravljenju niso pokazali znakov preobčutljivosti.
This vial contains recombinant human hyaluronidase.
Ta viala vsebuje rekombinantno humano hialuronidazo.
Known systemic hypersensitivity to hyaluronidase or recombinant human hyaluronidase.
Znana sistemska preobčutljivost na hialuronidazo ali rekombinantno humano hialuronidazo.
• Remove the needle cover.
• Snemite pokrovček injekcijske igle.
Distribution of the IgG subclasses (approx. values): IgG1  56.9%
vrednosti): IgG1 ≥ 56,9 %
This may have to be considered for patients who are on a controlled sodium diet.
To morajo morda upoštevati bolniki z nadzorovanim vnosom natrija.
The following rare side effects have been observed in patients using medicines like human normal immunoglobulin 10% given into a vein (intravenously).
Naslednji redki neželeni učinki so bili ugotovljeni pri infuzijah zdravil, ki so podobna humanemu polispecifičnemu imunoglobulinu 10 %, v veno (intravensko).
• Remove the smaller sterile syringe from package and attach to a non-vented spike or needle (device).
• Vzemite manjšo sterilno injekcijsko brizgo iz ovojnine in jo nataknite na neprezračevano konico ali injekcijsko iglo (pripomoček).
Items include: dual vial unit(s) of HyQvia, infusion supplies (subcutaneous needle set, solution container (bag or syringe), sterile clear bandage and tape, pump tubing, transfer devices, syringes, gauze and tape), sharps container, pump, and treatment logbook and other supplies as needed.
To so: enota(e) z dvema vialama zdravila HyQvia, infuzijske potrebščine (komplet subkutanih injekcijskih igel, vsebnik z raztopino (vreča ali brizga), sterilen prozoren obliž in trak, cevje za črpalko, naprava za prenos, brizge, gaza in trak), posoda za ostre predmete, črpalka, dnevnik zdravljenja in drugi pripomočki, če so potrebni.
• Remove the needle set by loosening the dressing on all edges.
• Komplet injekcijske igle snemite tako, da razrahljate obliž na vseh robovih.
Flush the pump tubing when the infusion is complete if instructed by your healthcare professional:
Ko je infuzija končana, cevko črpalke izperite po navodilu zdravstvenega delavca:
• Visually inspect both components of HyQvia for discoloration and particulate matter prior to administration.
• Pred dajanjem vizualno preglejte obe komponenti zdravila HyQvia, da nimata spremenjene barve in prisotnih delcev.
• Push the plunger of smaller syringe to remove the air and fill the needle set up to the needle wings with the recombinant human hyaluronidase.
• Potisnite bat manjše brizge, da odstranite zrak in iglo do metuljčka napolnite z rekombinantno humano hialuronidazo.
HyQvia is a dual vial unit consisting of one vial of human normal immunoglobulin (Immune Globulin 10% or IG 10%) and one vial of recombinant human hyaluronidase (rHuPH20).
HyQvia je enota z dvema vialama, ena viala vsebuje humani polispecifični imunoglobulin (imunoglobulin 10 % ali IG 10 %), druga viala pa vsebuje rekombinantno humano hialuronidazo (rHuPH20).
• Secure needle in place with sterile tape.
• Iglo pritrdite s sterilnim trakom.
• Rotate infusion sites by choosing opposite sides of the body between future infusions.
• Mesta infundiranja menjajte tako, da pri naslednji infuziji izberete mesto na nasprotni strani telesa.
VIAL LABEL RECOMBINANT HUMAN HYALURONIDASE (1.25 ML)
NALEPKA NA VIALI REKOMBINANTNE HUMANE HIALURONIDAZE (1,25 ML)
First, the full dose of recombinant human hyaluronidase solution is infused at a rate of 1 to 2 ml/minute per infusion site or as tolerated.
Najprej infundirajte celotni odmerek raztopine rekombinantne humane hialuronidaze s hitrostjo od 1 do 2 ml/minuto na mesto infundiranja ali kolikor bolnik prenese.
Oedema (including peripheral, swelling), chills, hyperhidrosis
Edem (vključno s perifernim, otekanje), mrzlica, hiperhidroza pekoč občutek
o The human normal immunoglobulin 10% should be clear and colourless or pale yellow.
 Raztopina humanega polispecifičnega imunoglobulina 10 % mora biti bistra in brezbarvna ali bledo rumena.
You may have to wait for up to 1 year after receiving HyQvia before you can receive your measles vaccine.
Po prejemanju zdravila HyQvia boste mogoče morali počakati do 1 leta, preden lahko prejmete cepivo proti ošpicam.
In particular, patients naive to human normal immunoglobulin, patients switched from an alternative immunoglobulin product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs.
pri katerih opravljamo prehod z drugega zdravila, in bolnike, pri katerih je od prejšnje infuzije minilo dolgo časa, pa je še zlasti treba spremljati med prvo infuzijo in v prvi uri po prvi infuziji, da bi ugotovili znake morebitnih neželenih učinkov.
Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infectious agents cannot be totally excluded.
Kljub temu pri dajanju zdravil, pripravljenih iz človeške krvi ali plazme, ni mogoče popolnoma izključiti prenosa povzročiteljev nalezljivih bolezni.
• If instructed by your healthcare professional, attach a saline bag to the pump tubing/needle set to push the human normal immunoglobulin 10% up to the needle wings.
• Če vam je zdravstveni delavec tako naročil, na cevko črpalke/komplet igle priključite vrečo fiziološke raztopine, da potisnete humani polispecifični imunoglobulin 10 % do metuljčka igle.
The dose required to achieve a trough level of 6 g/l is of the order of 0.4-0.8 g/kg body weight per month.
Bolniki, ki še niso prejemali imunoglobulinskega zdravljenja Odmerek, s katerim dosežete najnižjo koncentracijo 6 g/l, je razreda velikosti od 0,4 do 0,8 g/kg telesne mase na mesec.
• Insert needle completely to the wings of the needle with a rapid motion straight into the skin at a 90-degree angle.
• S hitrim gibom iglo uvedite naravnost v kožo do metuljčka pod kotom 90 stopinj.